Market Overview:
The global pasireotide drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of pituitary tumors, rising demand for better treatment options, and growing awareness about pituitary diseases. The global pasireotide drugs market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into 0.3mg/ml, 0.6mg/ml, and 0.9mg/ml segments. On the basis of application, the market is segmented into hospital and pharmacy segments. The hospital segment dominates this market owing to increased use in various endocrine surgeries such as transsphenoidal surgery for pituitary adenomas removal or debulking procedures for acromegaly patients who are not responsive to medical therapy alone or have residual tumor mass after surgery.
Product Definition:
Pasireotide is a drug used to treat Cushing's syndrome, diabetes mellitus, and acromegaly. It is a synthetic analog of somatostatin.
0.3mg/ml:
Pasireotide, also known as 5-ALA is a naturally occurring amino acid. It is manufactured by the human body and found in various foods such as meat, eggs, soy products and green vegetables. The drug Pasireotide (S-5-hydroxytryptophan) has been approved by the U.S Food and Drug Administration (FDA) for treatment of Gout arthritis which is characterized by recurrent attacks of gouty arthritis due to joint inflammation.
0.6mg/ml:
Pasireotide is used for the treatment of acromegaly and pituitary tumors. It works by increasing levels of growth hormone by inhibiting the somatostatin receptor in the brain. The drug was approved in Japan in 1997 and has been available since then, but it gained popularity only after its approval overseas.
Application Insights:
The hospital application segment held the largest share of over 70.0% in 2017. The growing number of patients suffering from chronic pancreatitis and ascites as a result of various diseases, such as cystic fibrosis, liver failure and cirrhosis are the major factors driving the demand for pasireotide drugs in this segment. In addition, an increase in surgical procedures is also expected to contribute to market growth during the forecast period.
Pharmacy Pasireotide drugs are primarily used for treating acute pancreatitis or chronic pancreatitis that has failed to respond to other treatments such as antibiotics and steroids. These drugs help reduce inflammation by inhibiting prostaglandin E2 production which reduces pain & fever associated with acute or chronic pancreatitis respectively (1). Other applications include use in diabetes mellitus type 1 & 2, biliary disorders including cholangiopathy and cholecystectomy among others (2).
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of Pasireotide-based product manufacturers and high healthcare expenditure. The region is expected to maintain its dominance over the forecast period due to increasing R&D activities, rising adoption of advanced technologies, and growing demand for cost-effective drugs.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to improving economic conditions in emerging countries such as China & India. Furthermore, increasing healthcare expenditure by governments & private sectors coupled with rising patient awareness levels regarding chronic diseases are some other factors driving regional growth.
Growth Factors:
- Increasing prevalence of Cushing's syndrome: The global incidence of Cushing's syndrome is estimated to be around one in 20,000 people. However, the true incidence is unknown as many cases are undiagnosed or misdiagnosed. The number of people with Cushing's syndrome is increasing due to the growing aging population and rising obesity rates.
- Unmet needs in the treatment of Cushing's syndrome: There are currently no approved therapies for the long-term treatment of pediatric or adult patients with refractory/relapsed disease or those who are intolerant to first-line therapy. Pasireotide drugs offer a potential new treatment option for these patients.
- Growing awareness and diagnosis of Cushing's syndrome: There has been growing awareness among healthcare professionals about the symptoms and diagnosis of Custing's Syndrome in recent years thanks to initiatives by patient advocacy groups and medical societies such as Endocrine Society and European Society for Endocrinology . This is likely contributing to increased diagnoses rates and will help drive demand for pasireotide drugs in future years
Scope Of The Report
Report Attributes
Report Details
Report Title
Pasireotide Drugs Market Research Report
By Type
0.3mg/ml, 0.6mg/ml, 0.9mg/ml
By Application
Hospital, Pharmacy
By Companies
Novartis, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Pasireotide Drugs Market Report Segments:
The global Pasireotide Drugs market is segmented on the basis of:
Types
0.3mg/ml, 0.6mg/ml, 0.9mg/ml
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Novartis
Highlights of The Pasireotide Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 0.3mg/ml
- 0.6mg/ml
- 0.9mg/ml
- By Application:
- Hospital
- Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pasireotide Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pasireotide drugs are a class of medications that are used to treat a variety of conditions, including heart failure and chronic kidney disease. These drugs work by improving the flow of blood through the body.
Some of the major companies in the pasireotide drugs market are Novartis, Novartis.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pasireotide Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Pasireotide Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Pasireotide Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Pasireotide Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Pasireotide Drugs Market Size & Forecast, 2020-2028 4.5.1 Pasireotide Drugs Market Size and Y-o-Y Growth 4.5.2 Pasireotide Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 0.3mg/ml
5.2.2 0.6mg/ml
5.2.3 0.9mg/ml
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pasireotide Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pasireotide Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 0.3mg/ml
9.6.2 0.6mg/ml
9.6.3 0.9mg/ml
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 0.3mg/ml
10.6.2 0.6mg/ml
10.6.3 0.9mg/ml
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 0.3mg/ml
11.6.2 0.6mg/ml
11.6.3 0.9mg/ml
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 0.3mg/ml
12.6.2 0.6mg/ml
12.6.3 0.9mg/ml
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 0.3mg/ml
13.6.2 0.6mg/ml
13.6.3 0.9mg/ml
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pasireotide Drugs Market: Competitive Dashboard
14.2 Global Pasireotide Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Novartis